Connect your AI

Innovate VATE Life Sciences — Related receivables from this subsidiary

Similar metrics at other companies

DCILife Sciences Segment — Equity investments in unconsolidated affiliates

$0—

TMOLife Sciences Solutions — Other segment items

$50M+11.1%

CNALife and Group — Reinsurance receivables

$56M-30.9%

RVTYLife Sciences — Acquisitions, earn outs and other

$24.5M—

PTCTLife Science — Interest Expense Nonoperating

$67.02M+30.5%

HMNLife And Health — Reinsurance balances receivable

$14.9M+4.9%

Other financials

Income statement

Revenue$364.8M+33.0%

Gross profit$53.5M+17.6%

Operating income$10.0M+194%

Net income-$16.8M+31.4%

EPS (diluted)-$1.29+31.7%

Balance sheet

Cash & equivalents$134.6M+297%

Total debt$1.4B+11.6%

Total equity-$256.3M-25.5%

Total assets$936.8M+7.9%

Cash flow

Operating cash flow$45.5M+423%

CapEx$200.0K-95.7%

Free cash flow$45.3M+341%

Valuation

Market cap$254.69M+196%

Enterprise value$1.52B+21.4%

P/S0.2×+0.1×

Profitability

Gross margin15.5%-3.8pp

Operating margin2.6%-1.2pp

Net margin-4%0.0pp

FCF margin15.7%—

Returns & leverage

Return on equity-8.1%—

Debt / equity1.7×—

Current ratio0.4×0.0×

Where this comes from

Reported directly by Innovate in its filing.

Tagged under the XBRL concept us-gaap:AccountsReceivableNet.

The official record: Innovate’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innovate's life sciences — related receivables from this subsidiary.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Innovate's life sciences — related receivables from this subsidiary?: Innovate (VATE) reported life sciences — related receivables from this subsidiary of $200K in Q1 2026.
What does life sciences — related receivables from this subsidiary mean?: This represents outstanding balances owed to the Life Sciences segment by affiliated entities or subsidiaries within the broader corporate structure. Monitoring these intercompany balances is critical for understanding internal capital flows and potential counterparty risk.